Systemic Nanoparticle Paclitaxel (nab-Paclitaxel) for In-stent Restenosis I (SNAPIST-I): A First-in-Human Safety and Dose-finding Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Systemic Nanoparticle Paclitaxel (nab-Paclitaxel) for In-stent Restenosis I (SNAPIST-I): A First-in-Human Safety and Dose-finding Study

Published:2007 Issue:4 Volume:30 Page:165-170
ISSN:0160-9289
Container-title:Clinical Cardiology
language:en
Short-container-title:Clin Cardiol

Author:

Margolis James,McDonald John,Heuser Richard,Klinke Peter,Waksman Ron,Virmani Renu,Desai Neil,Hilton David

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference17 articles.

2. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions

3. One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent

4. A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease

5. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-Coated Balloons for Treatment of Internal Carotid Artery Restenosis After Stenting: A Single-Center Mid-Term Outcome Study;CardioVascular and Interventional Radiology;2024-02-07

2. Minimally invasive surgical coronary artery revascularization—current status and future perspectives in an era of interventional advances;Journal of Visualized Surgery;2023-05

3. Repetition of Paclitaxel-Coated Devices for the Treatment of Lower Extremity Artery Disease: Mortality Outcomes and Predictors;ACTA CARDIOL SIN;2023

4. Regulators can we get DCB balloons approved for use in the United States?;Catheterization and Cardiovascular Interventions;2023-03

5. Arterial Revascularization;Limb Preservation for the Vascular Specialist;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3